<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023529</url>
  </required_header>
  <id_info>
    <org_study_id>2009-1684(REK)</org_study_id>
    <nct_id>NCT01023529</nct_id>
  </id_info>
  <brief_title>Symptoms and Quality of Life (QoL) After Palliative Pelvic Radiation of Prostate and Rectal Cancers</brief_title>
  <acronym>PallRad1</acronym>
  <official_title>A Prospective Multicenter Study of Symptoms and QOL in Patients With Prostate and Rectal Cancers Receiving Palliative Pelvic Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trondheim University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sorlandet Hospital HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of palliative pelvic radiation on symptoms
      and quality of life among patients with incurable prostate and rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the aging population, the prevalence of cancer is on the rise, leading to an increased
      demand for effective palliative treatment. There is little scientific information describing
      the effects of palliative radiotherapy among patients treated for soft-tissue tumors of the
      pelvis. This is a treatment that is used relatively frequently, but delivered heterogeneously
      since the optimum fractionation schedule has yet to be established. This study aims to define
      the effects of one such fractionation schedule (3Gy x 10-13) and thus, establish a foundation
      for future fractionation studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on patient's target symptom.</measure>
    <time_frame>at end of treatment and 6 weeks and 12 weeks after treatment completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on patient's QoL.</measure>
    <time_frame>at end of treatment and 6 and 12 weeks after treatment completion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in patient's symptoms and QoL.</measure>
    <time_frame>at end of treatment and 6 and 12 weeks after treatment completion.</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">98</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Prostate cancer</arm_group_label>
    <description>Patients with incurable prostate cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal Cancer</arm_group_label>
    <description>Patients with incurable rectal cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Palliative pelvic soft-tissue radiation (external beam)</intervention_name>
    <description>3 Gy x 10-13 (range 30 - 39 Gy total)</description>
    <arm_group_label>Prostate cancer</arm_group_label>
    <arm_group_label>Rectal Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Symptomatic patients referred for palliative pelvic radiotherapy of prostate and
        rectosigmoid cancers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age ≥ 18 years

          -  Histologically or cytologically proven adenocarcinoma of the prostate or rectosigmoid
             colon.

          -  Incurable disease (hormone-resistant in cases of prostate cancer)

          -  Life expectancy &gt; 3 months

          -  Symptomatic soft-tissue pelvic tumor mass (primary, recurrence or metastases)

          -  Planned fractionated radiotherapy (3Gy x 10-13)

          -  Written informed consent

        Exclusion criteria:

          -  Unable to fill out questionnaires (due to language or cognitive barriers)

          -  New systemic tumor-targeted treatment (hormone manipulation, chemotherapy, monoclonal
             antibodies, etc.) started within four weeks of baseline or during the 6 weeks
             immediately following pelvic radiotherapy.

          -  Previous pelvic radiotherapy

          -  The presence of a second primary pelvic cancer or other cancer requiring treatment

          -  Currently receiving treatment with an investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordland Hospital, Bodø</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innlandet Hospital Trust, Gjøvik</name>
      <address>
        <city>Gjøvik</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Treatment, Sorlandet Hospital HF</name>
      <address>
        <city>Kristiansand</city>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Center, Ullevål University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Northern Norway (Tromsø)</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olav's Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Rectal Neoplasms</keyword>
  <keyword>Palliative treatment</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

